June 15, 2018 / 12:12 PM / 5 months ago

Teva discontinues study for chronic headache treatment

June 15 (Reuters) - Teva Pharmaceutical Inc said on Friday it would discontinue a trial testing its drug for the treatment of chronic cluster headache, after an analysis revealed that the drug was unlikely to meet the main goal of the study.

Cluster headaches occur in cyclical patterns, or clusters, and are one of the most painful types of headaches.

The drug, fremanezumab, is under review by the U.S. FDA for the preventative treatment of migraine in adults. (Reporting by Manas Mishra in Bengaluru; Editing by Anil D’Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below